ANAB logo

AnaptysBio (ANAB) Cash From Investing

Annual CFI

$144.75 M
+$539.60 M+136.66%

December 31, 2023

Summary

Performance

1-Year Change

+136.66%

3-Year Change

+53.22%

5-Year Change

+201.62%

15-Year Change

+159.56%

ANAB Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

96.2%
ANAB annual cash flow from investing activities is higher than 96.2% of companies in Healthcare sector

High & Low

All-time High

$144.75 M
ANAB annual cash flow from investing activities is currently at an all-time high

3-Year Low

-$394.85 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
ANAB previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 11, 2025
ANAB next annual earnings announcement is scheduled for Mar 11, 2025

OtherANABcash flowmetrics:

Annual CFF

-$59.30 M
ANAB annual cash flow from financing activities is -$59.30 million

Annual CFO

-$120.80 M
ANAB annual cash flow from operations is -$120.80 million

Annual FCF

-$121.61 M
ANAB annual free cash flow is -$121.61 million

Annual CAPEX

$807.00 K
ANAB annual capital expenditures is $807.00 thousand

Quarterly CFI

$58.62 M
+$61.06 M+2500.49%

September 1, 2024

Summary

Performance

3-Month Change

+2500.49%

1-Year Change

-14.57%

3-Year Change

+440.82%

5-Year Change

-2.08%

ANAB Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

96.34%
ANAB quarterly cash flow from investing activities is higher than 96.34% of companies in Healthcare sector

High & Low

All-time High

$85.40 M
ANAB quarterly cash flow from investing activities is currently -31.36% below its historical high of $85.40 million

3-Year Low

-$312.91 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
ANAB previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

Mar 11, 2025
ANAB next earnings announcement is scheduled for Mar 11, 2025

OtherANABcash flowmetrics:

Quarterly CFF

$71.23 M
ANAB quarterly cash flow from financing activities is $71.23 million

Quarterly CFO

-$10.09 M
ANAB quarterly cash flow from operations is -$10.09 million

Quarterly FCF

-$10.13 M
ANAB quarterly free cash flow is -$10.13 million

Quarterly CAPEX

$35.00 K
ANAB quarterly capital expenditures is $35.00 thousand

TTM CFI

$173.97 M
+$27.98 M+19.17%

September 1, 2024

Summary

Performance

3-Month Change

+19.17%

1-Year Change

+35.94%

3-Year Change

+59.42%

5-Year Change

+32.37%

ANAB TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

97.16%
ANAB TTM cash flow from investing activities is higher than 97.16% of companies in Healthcare sector

High & Low

All-time High

$173.97 M
ANAB TTM cash flow from investing activities is currently at an all-time high

3-Year Low

-$483.04 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
ANAB previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

Mar 11, 2025
ANAB next earnings announcement is scheduled for Mar 11, 2025

OtherANABcash flowmetrics:

TTM CFF

$94.33 M
ANAB TTM cash flow from financing activities is $94.33 million

TTM CFO

-$103.01 M
ANAB TTM cash flow from operations is -$103.01 million

TTM FCF

-$103.39 M
ANAB TTM free cash flow is -$103.39 million

TTM CAPEX

$375.00 K
ANAB TTM capital expenditures is $375.00 thousand

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

ANAB Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+136.7%-14.6%+35.9%
3 y3 years+53.2%+440.8%+59.4%
5 y5 years+201.6%-2.1%+32.4%

ANAB Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+136.7%-31.4%+118.7%at high+136.0%
5 y5-yearat high+136.7%-31.4%+118.7%at high+136.0%
alltimeall timeat high+136.7%-31.4%+118.7%at high+136.0%

AnaptysBio Cash From Investing History

DateAnnualQuarterlyTTM
Sep 2024
-
$58.62 M(-2500.5%)
$173.97 M(+19.2%)
Jun 2024
-
-$2.44 M(-103.6%)
$145.99 M(+14.1%)
Mar 2024
-
$68.62 M(+39.5%)
$127.97 M(-11.6%)
Dec 2023
$144.75 M(-136.7%)
$49.18 M(+60.5%)
$144.75 M(+23.6%)
Sep 2023
-
$30.64 M(-249.8%)
$117.07 M(+116.8%)
Jun 2023
-
-$20.45 M(-124.0%)
$54.00 M(+1459.5%)
Mar 2023
-
$85.40 M(+297.2%)
$3.46 M(-100.9%)
Dec 2022
-$394.85 M(-1116.7%)
$21.50 M(-166.3%)
-$394.85 M(-18.3%)
Sep 2022
-
-$32.43 M(-54.3%)
-$483.04 M(+9.8%)
Jun 2022
-
-$71.00 M(-77.3%)
-$439.76 M(+32.9%)
Mar 2022
-
-$312.91 M(+369.2%)
-$330.81 M(-951.8%)
Dec 2021
$38.84 M(-58.9%)
-$66.69 M(-715.3%)
$38.84 M(-64.4%)
Sep 2021
-
$10.84 M(-71.4%)
$109.13 M(+5.9%)
Jun 2021
-
$37.96 M(-33.1%)
$103.02 M(-26.7%)
Mar 2021
-
$56.73 M(+1476.7%)
$140.45 M(+48.7%)
Dec 2020
$94.47 M(-28.1%)
$3.60 M(-24.0%)
$94.47 M(-0.5%)
Sep 2020
-
$4.73 M(-93.7%)
$94.91 M(-36.7%)
Jun 2020
-
$75.39 M(+601.3%)
$150.04 M(+13.2%)
Mar 2020
-
$10.75 M(+166.4%)
$132.53 M(+0.8%)
Dec 2019
$131.43 M
$4.04 M(-93.3%)
$131.43 M(-439.1%)
DateAnnualQuarterlyTTM
Sep 2019
-
$59.86 M(+3.4%)
-$38.75 M(-47.6%)
Jun 2019
-
$57.88 M(+499.3%)
-$74.00 M(-45.2%)
Mar 2019
-
$9.66 M(-105.8%)
-$134.94 M(-5.3%)
Dec 2018
-$142.45 M(-41.4%)
-$166.15 M(-775.0%)
-$142.45 M(+10.1%)
Sep 2018
-
$24.61 M(-903.9%)
-$129.36 M(-16.3%)
Jun 2018
-
-$3.06 M(-242.7%)
-$154.47 M(-27.8%)
Mar 2018
-
$2.15 M(-101.4%)
-$213.83 M(-12.0%)
Dec 2017
-$243.06 M(>+9900.0%)
-$153.06 M(>+9900.0%)
-$243.06 M(+170.1%)
Sep 2017
-
-$495.00 K(-99.2%)
-$90.00 M(+0.6%)
Jun 2017
-
-$62.42 M(+130.5%)
-$89.51 M(+230.3%)
Mar 2017
-
-$27.09 M(>+9900.0%)
-$27.10 M(>+9900.0%)
Dec 2016
-$50.00 K(-79.0%)
-$1000.00(<-9900.0%)
-$50.00 K(-45.1%)
Sep 2016
-
$0.00(-100.0%)
-$91.00 K(-48.0%)
Jun 2016
-
-$14.00 K(-60.0%)
-$175.00 K(-9.3%)
Mar 2016
-
-$35.00 K(-16.7%)
-$193.00 K(-18.9%)
Dec 2015
-$238.00 K(+70.0%)
-$42.00 K(-50.0%)
-$238.00 K(+21.4%)
Sep 2015
-
-$84.00 K(+162.5%)
-$196.00 K(+75.0%)
Jun 2015
-
-$32.00 K(-60.0%)
-$112.00 K(+40.0%)
Mar 2015
-
-$80.00 K
-$80.00 K
Dec 2014
-$140.00 K(+278.4%)
-
-
Dec 2013
-$37.00 K
-
-

FAQ

  • What is AnaptysBio annual cash flow from investing activities?
  • What is the all time high annual CFI for AnaptysBio?
  • What is AnaptysBio annual CFI year-on-year change?
  • What is AnaptysBio quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for AnaptysBio?
  • What is AnaptysBio quarterly CFI year-on-year change?
  • What is AnaptysBio TTM cash flow from investing activities?
  • What is the all time high TTM CFI for AnaptysBio?
  • What is AnaptysBio TTM CFI year-on-year change?

What is AnaptysBio annual cash flow from investing activities?

The current annual CFI of ANAB is $144.75 M

What is the all time high annual CFI for AnaptysBio?

AnaptysBio all-time high annual cash flow from investing activities is $144.75 M

What is AnaptysBio annual CFI year-on-year change?

Over the past year, ANAB annual cash flow from investing activities has changed by +$539.60 M (+136.66%)

What is AnaptysBio quarterly cash flow from investing activities?

The current quarterly CFI of ANAB is $58.62 M

What is the all time high quarterly CFI for AnaptysBio?

AnaptysBio all-time high quarterly cash flow from investing activities is $85.40 M

What is AnaptysBio quarterly CFI year-on-year change?

Over the past year, ANAB quarterly cash flow from investing activities has changed by -$10.00 M (-14.57%)

What is AnaptysBio TTM cash flow from investing activities?

The current TTM CFI of ANAB is $173.97 M

What is the all time high TTM CFI for AnaptysBio?

AnaptysBio all-time high TTM cash flow from investing activities is $173.97 M

What is AnaptysBio TTM CFI year-on-year change?

Over the past year, ANAB TTM cash flow from investing activities has changed by +$46.00 M (+35.94%)